

Name: Suzana Giffin, AVP
Company/Organization: Merck & Co., Inc.
Address: 2000 Galloping Hill Rd, Kenilworth, NJ 07033
Phone: 908-740-6708
Email: suzana.giffin@merck.com
Date of Request: June 25, 2020
NCCN Guidelines Panel: Non-Melanoma Skin Cancer Panel

NCCN Non-Melanoma Skin Cancer Panel: On behalf of Merck & Co., Inc., I respectfully request the NCCN Non-Melanoma Skin Cancer Panel to review the enclosed information for KEYTRUDA, in reference to treatment of patients with cutaneous squamous cell carcinoma (cSCC).

Specific Changes: We respectfully request the NCCN Non-Melanoma Skin Cancer Panel to consider updating the NCCN Guidelines to include KEYTRUDA as a treatment option for patients with recurrent or metastatic cSCC that is not curable by surgery or radiation.

FDA Clearance: KEYTRUDA is approved for the treatment of patients with recurrent or metastatic cSCC that is not curable by surgery or radiation.

Rationale: KEYTRUDA is now approved for the treatment of patients with recurrent or metastatic cSCC that is not curable by surgery or radiation.

The following resources are submitted to assist the committee with their review.

1. KEYTRUDA (pembrolizumab) prescribing information. Merck & Co., Inc.

Thank you for considering this request. Below is my contact information should you need to contact me for additional information.

Sincerely,



Suzana Giffin, AVP
Global Medical Affairs
Merck & Co., Inc.
2000 Galloping Hill Rd
Kenilworth, NJ 07033
908-740-6708
suzana.giffin@merck.com